Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 137

Related Citations for PubMed (Select 21564444)

1.

The safety and efficacy of botulinum toxin-A in the management of bladder oversensitivity: a randomised double-blind placebo-controlled trial.

Dowson C, Sahai A, Watkins J, Dasgupta P, Khan MS.

Int J Clin Pract. 2011 Jun;65(6):698-704. doi: 10.1111/j.1742-1241.2011.02663.x.

PMID:
21564444
2.

Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial.

Cruz F, Herschorn S, Aliotta P, Brin M, Thompson C, Lam W, Daniell G, Heesakkers J, Haag-Molkenteller C.

Eur Urol. 2011 Oct;60(4):742-50. doi: 10.1016/j.eururo.2011.07.002. Epub 2011 Jul 13.

PMID:
21798658
3.

OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.

Chapple C, Sievert KD, MacDiarmid S, Khullar V, Radziszewski P, Nardo C, Thompson C, Zhou J, Haag-Molkenteller C.

Eur Urol. 2013 Aug;64(2):249-56. doi: 10.1016/j.eururo.2013.04.001. Epub 2013 Apr 10.

PMID:
23608668
4.

Improvement in quality of life after botulinum toxin-A injections for idiopathic detrusor overactivity: results from a randomized double-blind placebo-controlled trial.

Sahai A, Dowson C, Khan MS, Dasgupta P.

BJU Int. 2009 Jun;103(11):1509-15. doi: 10.1111/j.1464-410X.2009.08402.x. Epub 2009 Apr 15.

PMID:
19389019
5.

Botulinum toxin a versus placebo for refractory detrusor overactivity in women: a randomised blinded placebo-controlled trial of 240 women (the RELAX study).

Tincello DG, Kenyon S, Abrams KR, Mayne C, Toozs-Hobson P, Taylor D, Slack M.

Eur Urol. 2012 Sep;62(3):507-14. doi: 10.1016/j.eururo.2011.12.056. Epub 2012 Jan 5.

PMID:
22236796
7.

Efficacy and safety of low doses of onabotulinumtoxinA for the treatment of refractory idiopathic overactive bladder: a multicentre, double-blind, randomised, placebo-controlled dose-ranging study.

Denys P, Le Normand L, Ghout I, Costa P, Chartier-Kastler E, Grise P, Hermieu JF, Amarenco G, Karsenty G, Saussine C, Barbot F; VESITOX study group in France.

Eur Urol. 2012 Mar;61(3):520-9. doi: 10.1016/j.eururo.2011.10.028. Epub 2011 Oct 25.

PMID:
22036776
8.

Outcome of a randomized, double-blind, placebo controlled trial of botulinum A toxin for refractory overactive bladder.

Flynn MK, Amundsen CL, Perevich M, Liu F, Webster GD.

J Urol. 2009 Jun;181(6):2608-15. doi: 10.1016/j.juro.2009.01.117. Epub 2009 Apr 16.

9.

Repeated injections of botulinum toxin-A for idiopathic detrusor overactivity.

Sahai A, Dowson C, Khan MS, Dasgupta P; GKT Botulinum Study Group.

Urology. 2010 Mar;75(3):552-8. doi: 10.1016/j.urology.2009.05.097. Epub 2009 Dec 29.

PMID:
20035984
10.

Botulinum toxin injections for adults with overactive bladder syndrome.

Duthie JB, Vincent M, Herbison GP, Wilson DI, Wilson D.

Cochrane Database Syst Rev. 2011 Dec 7;(12):CD005493. doi: 10.1002/14651858.CD005493.pub3. Review.

PMID:
22161392
11.

Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review.

Karsenty G, Denys P, Amarenco G, De Seze M, Gamé X, Haab F, Kerdraon J, Perrouin-Verbe B, Ruffion A, Saussine C, Soler JM, Schurch B, Chartier-Kastler E.

Eur Urol. 2008 Feb;53(2):275-87. Epub 2007 Oct 16. Review.

PMID:
17988791
12.
13.

Urodynamic assessment of poor responders after botulinum toxin-A treatment for overactive bladder.

Sahai A, Khan MS, Le Gall N, Dasgupta P; GKT Botulinum Study Group.

Urology. 2008 Mar;71(3):455-9. doi: 10.1016/j.urology.2007.11.039.

PMID:
18342186
14.

Role of botulinum toxin-A in refractory idiopathic overactive bladder patients without detrusor overactivity.

Kanagarajah P, Ayyathurai R, Caruso DJ, Gomez C, Gousse AE.

Int Urol Nephrol. 2012 Feb;44(1):91-7. doi: 10.1007/s11255-011-9979-9. Epub 2011 Jun 4.

PMID:
21643644
15.
16.

Treatment satisfaction and improvement in health-related quality of life with onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity.

Sussman D, Patel V, Del Popolo G, Lam W, Globe D, Pommerville P.

Neurourol Urodyn. 2013 Mar;32(3):242-9. doi: 10.1002/nau.22293. Epub 2012 Sep 10.

PMID:
22965657
17.
18.

Botulinum toxin injections for adults with overactive bladder syndrome.

Duthie J, Wilson DI, Herbison GP, Wilson D.

Cochrane Database Syst Rev. 2007 Jul 18;(3):CD005493. Review. Update in: Cochrane Database Syst Rev. 2011;(12):CD005493.

PMID:
17636801
19.

Urodynamic results and clinical outcomes with intradetrusor injections of onabotulinumtoxinA in a randomized, placebo-controlled dose-finding study in idiopathic overactive bladder.

Rovner E, Kennelly M, Schulte-Baukloh H, Zhou J, Haag-Molkenteller C, Dasgupta P.

Neurourol Urodyn. 2011 Apr;30(4):556-62. doi: 10.1002/nau.21021. Epub 2011 Feb 23.

PMID:
21351127
20.

Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial.

Dmochowski R, Chapple C, Nitti VW, Chancellor M, Everaert K, Thompson C, Daniell G, Zhou J, Haag-Molkenteller C.

J Urol. 2010 Dec;184(6):2416-22. doi: 10.1016/j.juro.2010.08.021. Epub 2010 Oct 16.

PMID:
20952013
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk